Latest booster reduces adults' risk of moderate or severe COVID by more than half
01 Mar 2024
VaccineEmergency Use Authorization
The most recent COVID-19 booster shot reduces adults' risk of moderate or severe COVID by more than half, according to a new nationwide data study from September 2023 through January 2024, a period of JN.1 variant dominance. The new study is one of the first to evaluate protection provided by the updated shot against COVID-19-associated emergency department and urgent care visits (markers for moderate disease) and against hospitalizations (a marker for severe disease), in individuals 18 and older, due to JN.1, the most recently predominant strain of COVID.
The most recent COVID-19 booster shot reduces adults' risk of moderate or severe COVID by more than half, according to a new nationwide data study from September 2023 through January 2024, a period of JN.1 variant dominance.
The new study is one of the first to evaluate protection provided by the updated shot against COVID-19-associated emergency department and urgent care visits (markers for moderate disease) and against hospitalizations (a marker for severe disease), in individuals 18 and older, due to JN.1, the most recently predominant strain of COVID.
"Halving your risk of needing to visit an E.D. or urgent care center or to be treated in the hospital for COVID is significant," said study co-author Shaun Grannis, M.D., M.S., Regenstrief Institute vice president for data and analytics and a professor at Indiana University School of Medicine. "As an informatician I want to highlight that the data we analyzed came from different populations and geographic locations, adults of all ages and the most recent COVID strain. This analysis strongly supports the benefit of getting a booster shot and as a clinician, I encourage my patients to do so."
"These are encouraging findings," said study co-author Brian Dixon, PhD, MPA, interim director of Regenstrief Institute's Clem McDonald Center for Biomedical Informatics and professor at Indiana University Richard M. Fairbanks School of Public Health. "These estimates of vaccine effectiveness are what we would expect for an annual booster designed for an endemic virus that continues to evolve. We looked at a longer time period than similar studies in Europe, and we found good performance. Yet we do need to be alert to the presumed waning of the updated booster's effectiveness, which we have seen in earlier COVID-19 vaccines. Americans should expect the CDC to recommend future boosters, likely on an annual schedule."
These findings of protection against moderate and severe disease provided by the booster in this large study are consistent with those of an earlier, small scale study of individuals seen for testing at a pharmacy. That study did not include hospitalized patients.
The authors of the new study, co-authored by Drs. Grannis and Dixon, concluded, "In this analysis of updated COVID-19 VE [vaccine effectiveness], receipt of an updated COVID-19 vaccine dose provided protection against COVID-19-associated ED/UC [emergency department/critical care] visits and hospitalizations among immunocompetent adults. CDC will continue monitoring VE of updated COVID-19 vaccines. All adults should stay up to date with recommended COVID-19 vaccines, including receiving a dose of updated vaccine."
"Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years -- VISION and IVY Networks, September 2023-January 2024" is published in Morbidity and Mortality Report (MMWR). The study was funded by the CDC.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.